Table 2B.

AACR GENIE squamous cell lung cancer co-occurring mutations

All squamous cell lung cancer (n = 559 samples)
TP53 mutationa438 (78.4%)
KMT2D mutationb96 (17.2%)
CDKN2A mutationc88 (15.7%)
MutationsdAll TP53 mutations n = 287 samples (297 missense mutations)Lung-enriched TP53 mutations (V157, R158, A159) n = 35 samples (35 missense mutations)
TP53 without KMT2D or CDKN2A182 (63.4%)17 (48.6%)
TP53 and KMT2D59 (20.6%)9 (25.7%)
TP53 and CDKN2A59 (20.6%)11 (31.4%)
TP53, CDKN2A, and KMT2D13 (4.5%)2 (5.7%)
  • aTP53 mutations include 435 samples with mutations, 2 samples with fusions, and 1 sample with multiple alterations.

  • bKMT2D mutations include 94 samples with mutations, 1 sample with fusions, and 1 sample with multiple alterations.

  • cCDKN2A mutations include 86 samples with mutations and 2 samples with fusions.

  • Amplifications and deep deletions are excluded.

  • dFrequency is represented in percent of samples with missense mutations out of total number of samples with TP53 missense mutations.